Read This First
This page is not built on clinical evidence. Cost and access are commercial and legal facts, not scientific findings. They come from the regulatory record, which for this compound moved in July 2026 without settling anything.
Epitalon has no list price, no prescription route, no insurance pathway and no manufacturer, because it is not approved anywhere, has no human safety data by any route, and is not on the list of substances pharmacies may compound.1 An advisory committee has recommended adding it for insomnia. The FDA has not acted.
This page publishes no prices. What follows is what determines the money, and for this compound the money is mostly determined by a word: telomere.
Why There Is No Price
What a Price Normally Represents
For an approved medicine, a price sits on top of a known quantity of a known substance, made to a validated standard, for a stated indication, with a documented effect. For epitalon, the substance is a four-residue peptide that is cheap to make and easy to identify; everything above that is missing. There is no standard, no indication, and no documented effect in a human being beyond a change in a urinary melatonin metabolite in 20 shift workers.1
Pricing a Telomere
Epitalon is sold as an anti-ageing compound at prices that bear no relation to four amino acids, because the product is not the peptide but the claim: that it activates telomerase and lengthens telomeres, and that longer telomeres mean a longer life. The first half rests on one cell culture paper from 2003, never independently replicated.2 The second half is not established in humans, and the FDA's stated safety concern is precisely that chronic telomere lengthening "could enable cells to evade senescence and become cancerous."1
The premium is for the mechanism. The mechanism is the risk.
Access
Is There a Legal Route?
Not in the United States. Epitalon is not approved, is not a component of an approved drug, and is not on the 503A bulks list. It sat in the FDA's Category 2 of nominated compounding substances from September 2023 and is now listed as nominated but withdrawn.3 There is no clinical trial to join; none is registered.4
What Did the July 2026 Vote Do?
On 24 July 2026 the FDA's advisory committee voted 7 to 4, with one abstention, to recommend epitalon for the bulks list for insomnia, over the FDA's objection on every criterion it evaluates.51 The recommendation is advisory, the list can only be amended by rulemaking, and the FDA has not begun one. If it eventually acts, a subcutaneous injection would become compoundable on prescription for insomnia, from pharmacies that would first need to source characterised material.
Two things about that are worth noticing. The use recommended was insomnia, for which no study of epitalon exists. And the use it is actually sold for, anti-ageing, was not before the committee and would not be covered.
Does Insurance Cover It?
No, and there is nothing to appeal. Payers reimburse approved products for approved indications. A compounded product on a bulks list, if it ever exists, would still not be an approved drug, and compounded preparations generally fall outside pharmacy benefit coverage.
Can HSA or FSA Funds Be Used?
Tax-advantaged health accounts cover qualified medical expenses, which generally requires a legitimate medical purpose and often a provider's documentation. A product that cannot lawfully be dispensed for human use sits poorly against that. The account holder carries the consequences of a disallowed expense; the question belongs with the plan administrator.
What the Money Buys
Where Does the Spread Between Sellers Come From?
| Cost component | Present in | What it buys |
|---|---|---|
| Consultation and clinician time | Clinics, concierge practices | A history, an examination, a record, and someone accountable |
| Premises, staff and liability | Clinics | Overhead and recourse, not product |
| The "longevity protocol" | Clinics, vendors | Epitalon bundled with other compounds and tests, priced together so none is examined alone |
| The epithalamin literature | All channels, in the copy | Nothing; the human data belong to a gland extract, not to the tetrapeptide6 |
| Marketing and affiliate commission | All channels, often invisible | Nothing for the buyer |
| The compound itself | All channels | Four amino acids of unverified sterility, at a cost small relative to the components above it. ONPEPS publishes no prices; read this as reasoning about cost structure rather than a measured breakdown |
None of the spread buys verified product quality, because no channel offers that. A higher price buys service and accountability where those exist. It does not buy a human data point, because for injected epitalon none exists.
Why Is the Course Structure Cheap and the Programme Expensive?
Epitalon is sold in short courses, typically ten days, repeated once or twice a year, a schedule borrowed from the mouse studies and from Russian use of the extract.7 A single course uses little peptide. The programme is open-ended by design, because the claim is about ageing, which does not stop. A buyer is committing to an annual purchase for life, for a compound whose one lifetime study found the average mouse lived no longer.7
The Spending Decision
What Result Is Being Paid For?
Longer life, or slower ageing, or better sleep, depending on the page. In mice, epitalon did not change mean lifespan, extended the lifespan of the longest-lived tenth by 13 percent, and reduced leukaemia.7 In elderly humans, epithalamin, a different substance, was reported by the same group to reduce mortality over 12 years.6 In humans given epitalon, a melatonin metabolite changed in a 20-day study.1
The result being paid for, a longer or slower-ageing human life, is the one outcome that cannot be measured in any individual buyer. Nobody who takes epitalon will ever know whether it worked. That is not a criticism of the compound; it is a description of what makes an anti-ageing product easy to sell for decades.
A person who feels better on epitalon has felt better. A person who lives to 90 on epitalon has lived to 90. Neither observation is evidence, and the product's marketing depends on treating both as if they were.
What Is the Risk Side of the Ledger?
Unknown in humans, with one identified mechanism. The FDA found no human safety data at all and named telomere lengthening as a cancer concern, citing evidence that long telomeres are associated with increased malignancy risk.18 The mouse studies found fewer tumours, not more, which is reassuring as far as mice go and not far beyond.7 The honest position is that a person injecting a putative telomerase activator annually for decades is running an experiment with a cancer endpoint and no control group.
What Should Be Asked Before Paying?
Which human study of epitalon, the tetrapeptide, measured the outcome you are promising? If the answer cites a 12-year mortality study, it is citing epithalamin.6
Are you aware the FDA identified telomere lengthening as a cancer concern, and what is your view of it?1
Are you aware the July 2026 recommendation was for insomnia and has not been adopted, and on what legal basis are you supplying this?
Can I see a certificate for the batch I will receive, with sterility and endotoxin results?
Does anyone here earn commission on product sales?
What Would Change This Page
The FDA's Decision, or a Trial
The FDA's action on the July 2026 recommendation is the one scheduled event, and it would concern insomnia. A human trial of injected epitalon measuring any clinical outcome would be the first; none is registered. Independent replication of the telomerase finding would change the evidence page more than this one.
A Note on Price Comparisons
Figures circulate comparing epitalon favourably with other longevity interventions on a cost-per-year basis. A cost per year of an intervention with no measured human effect on any year is not a figure. ONPEPS does not make the comparison.
Related ONPEPS Coverage
Epitalon sourcing and quality: four residues, one laboratory, two names
MOTS-c cost and access: the other longevity peptide the committee recommended
FDA peptide news July 2026: the votes, the dissent and what happens next
Sources
US Food and Drug Administration. Epitalon-related bulk drug substances (epitalon (free base) and epitalon acetate): FDA presentation to the Pharmacy Compounding Advisory Committee, 24 July 2026. Docket FDA-2025-N-6895. fda.gov
Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. Paywalled. pubmed.ncbi.nlm.nih.gov/12937682
US Food and Drug Administration. Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Entry for epitalon. Content current as of 22 April 2026. fda.gov
ClinicalTrials.gov. Studies listing epitalon or epithalon as an intervention. Registry search returning no studies; checked 16 September 2026. clinicaltrials.gov
ONPEPS. FDA peptide news July 2026: the only source you need. Records the 7 to 4 vote with one abstention on epitalon. onpeps.com
Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med. 2006;142(3):356-359. Paywalled. Concerns epithalamin, not epitalon. pubmed.ncbi.nlm.nih.gov/17426848
Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. Paywalled. pubmed.ncbi.nlm.nih.gov/14501183
McNally EJ, Luncsford PJ, Armanios M. Long telomeres and cancer risk: the price of cellular immortality. J Clin Invest. 2019;129(9):3474-3481. Open access. pubmed.ncbi.nlm.nih.gov/31380804
Not Medical or Financial Advice
Epitalon is not approved for human use in any jurisdiction and has no human safety data by any route. Treatment decisions belong with a qualified healthcare provider. Nothing on this page is a recommendation to buy or not to buy anything; it is an account of what is known about what the money would be spent on.
Sources verified 16 September 2026. The FDA's action on the July 2026 recommendation would change the access section of this page. Re-verify before relying on anything here.